Floatz logo

Bosmolisib

Marginal Zone Lymphoma

Boryung Pharmaceutical Co., LtdSmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

106 Active assets in the Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Bosmolisib is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
CCC
Indicative ·
55 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
44 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →